Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Adenosylhomocysteinase | 0.0282 | 0.7275 | 0.5 |
Trichomonas vaginalis | poly(p)/ATP NAD kinase, putative | 0.0354 | 1 | 1 |
Mycobacterium tuberculosis | Inorganic polyphosphate/ATP-NAD kinase PpnK (poly(P)/ATP NAD kinase) | 0.0325 | 0.8909 | 1 |
Giardia lamblia | Inorganic polyphosphate/ATP-NAD kinase, putative | 0.0354 | 1 | 0.5 |
Trypanosoma cruzi | S-adenosylhomocysteine hydrolase, putative | 0.0282 | 0.7275 | 0.5 |
Toxoplasma gondii | S-Adenosyl homocysteine hydrolase | 0.0282 | 0.7275 | 0.5 |
Trypanosoma brucei | S-adenosylhomocysteine hydrolase, putative | 0.0282 | 0.7275 | 0.5 |
Leishmania major | S-adenosylhomocysteine hydrolase | 0.0282 | 0.7275 | 0.5 |
Mycobacterium leprae | Inorganic polyphosphate/ATP-NAD kinase PpnK (Poly(P)/ATP NAD kinase) | 0.0325 | 0.8909 | 1 |
Schistosoma mansoni | adenosylhomocysteinase | 0.0282 | 0.7275 | 0.5973 |
Schistosoma mansoni | poly(p)/ATP NAD kinase | 0.0354 | 1 | 1 |
Mycobacterium ulcerans | inorganic polyphosphate/ATP-NAD kinase | 0.0354 | 1 | 1 |
Trichomonas vaginalis | adenosylhomocysteinase, putative | 0.0282 | 0.7275 | 0.7275 |
Treponema pallidum | hypothetical protein | 0.0354 | 1 | 0.5 |
Entamoeba histolytica | adenosylhomocysteinase, putative | 0.0282 | 0.7275 | 0.5 |
Echinococcus multilocularis | NAD kinase | 0.0354 | 1 | 1 |
Plasmodium vivax | adenosylhomocysteinase(S-adenosyl-L-homocystein e hydrolase), putative | 0.0282 | 0.7275 | 0.5 |
Toxoplasma gondii | adenosylhomocysteinase, putative | 0.0282 | 0.7275 | 0.5 |
Loa Loa (eye worm) | adenosylhomocysteinase | 0.0282 | 0.7275 | 0.5 |
Trichomonas vaginalis | adenosylhomocysteinase, putative | 0.0282 | 0.7275 | 0.7275 |
Plasmodium falciparum | adenosylhomocysteinase | 0.0282 | 0.7275 | 0.5 |
Trichomonas vaginalis | poly(p)/ATP NAD kinase, putative | 0.0354 | 1 | 1 |
Trypanosoma cruzi | S-adenosylhomocysteine hydrolase, putative | 0.0282 | 0.7275 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.